Sphera Funds Management LTD. Sells 96,695 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR)

Sphera Funds Management LTD. reduced its stake in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) by 47.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 108,473 shares of the company’s stock after selling 96,695 shares during the quarter. Sphera Funds Management LTD. owned about 1.49% of Kezar Life Sciences worth $729,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Peapod Lane Capital LLC bought a new stake in Kezar Life Sciences during the fourth quarter worth approximately $833,000. BML Capital Management LLC bought a new position in shares of Kezar Life Sciences during the fourth quarter valued at approximately $327,000. Dimensional Fund Advisors LP bought a new position in shares of Kezar Life Sciences during the fourth quarter valued at approximately $217,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Kezar Life Sciences by 613.8% during the fourth quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock valued at $80,000 after buying an additional 10,219 shares during the last quarter. 67.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, William Blair reaffirmed an “outperform” rating on shares of Kezar Life Sciences in a research note on Friday, February 28th.

Kezar Life Sciences Trading Down 1.7%

KZR opened at $4.06 on Friday. The stock has a market cap of $29.66 million, a price-to-earnings ratio of -0.31 and a beta of 0.61. The stock’s 50 day moving average price is $4.67 and its 200-day moving average price is $5.97. Kezar Life Sciences, Inc. has a one year low of $3.62 and a one year high of $9.18. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65.

Kezar Life Sciences (NASDAQ:KZR) last released its earnings results on Tuesday, May 13th. The company reported ($2.27) EPS for the quarter, beating analysts’ consensus estimates of ($2.56) by $0.29. On average, equities analysts forecast that Kezar Life Sciences, Inc. will post -4.39 EPS for the current year.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.